Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without CirrhosisKris V. Kowdley, Michael Fried, Paul J. Pockros et al.|New England Journal of Medicine|2014Cited by 1.1k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary CholangitisFrederik Nevens, Д. А. Шапиро, Pietro Andreoné et al.|New England Journal of Medicine|2016Cited by 1.1k
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment OptionsIra M. Jacobson, David R. Nelson, Stuart C. Gordon et al.|New England Journal of Medicine|2013Cited by 1.1k
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with CirrhosisFred Poordad, Barry Bernstein, Christophe Hézode et al.|New England Journal of Medicine|2014Cited by 877
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept studyDavid Jones, Gideon M. Hirschfield, Pol Boudes et al.|The Lancet. Gastroenterology & hepatology|2017Cited by 186